BCMA-UCART

PreclinicalBiologic

BBioray Laboratories

BCMA-UCART is one of 49 biologic programs targeting Efficacy and Safety. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetySuspended

Efficacy and SafetyPreclinical

Suspended

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Tuoyi

SSun Yat-sen University

Phase 3

4 3

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 4

Busulfex

Akero Therapeutics

Phase 3

3 5

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 6

Oxycontin

PPurdue Pharma LP

Phase 3

1 7

Alka-Seltzer

AAbbott

Phase 3

1 8

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 9

Mitomycin C

GGynecologic Oncology Group

Phase 3

2 10

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Efficacy and Safety Evaluation of BCMA-UCART

Suspended·BBioray Laboratories·N/A·NCT03752541·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BCMA-UCART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCMA-UCART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCMA-UCART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioray Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: BBioray Laboratories

BCMA-UCART

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News